

Kathleen M Giacomini

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1457098/kathleen-m-giacomini-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

142
papers

10,303
citations

46
h-index

100
g-index

151
ext. papers

11,800
ext. citations

7.6
avg, IF

5.91
L-index

#	Paper	IF	Citations
142	High Throughput Screening of a Prescription Drug Library for Inhibitors of Organic Cation Transporter 3, OCT3.. <i>Pharmaceutical Research</i> , 2022 , 1	4.5	2
141	The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms.. <i>Clinical Pharmacology and Therapeutics</i> , 2022 ,	6.1	9
140	Mechanisms and genetics of drug transport 2022 , 213-239		0
139	Pharmacogenomic mechanisms of drug toxicity 2022 , 303-322		
138	Response to Comment on Dawed et al. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. <i>Diabetes Care</i> 2021;44:2673-2682.. <i>Diabetes Care</i> , 2022 , 45, e82-e83	14.6	
137	ORGANIC CATION AND ZWITTERION TRANSPORTERS 2022 , 9-32		
136	A Critical Overview of the Biological Effects of Excipients (Part I): Impact on Gastrointestinal Absorption.. <i>AAPS Journal</i> , 2022 , 24, 60	3.7	0
135	.. <i>Drug Metabolism and Disposition</i> , 2021 ,	4	4
134	Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. <i>Diabetes Care</i> , 2021 , 44, 2673-2682	14.6	5
133	The Effects of Genetic Mutations and Drugs on the Activity of the Thiamine Transporter, SLC19A2. <i>AAPS Journal</i> , 2021 , 23, 35	3.7	1
132	Opportunities and challenges for the computational interpretation of rare variation in clinically important genes. <i>American Journal of Human Genetics</i> , 2021 , 108, 535-548	11	10
131	Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics. <i>Clinical and Translational Science</i> , 2021 , 14, 1431-1443	4.9	2
130	Drugs in COVID-19 Clinical Trials: Predicting Transporter-Mediated Drug-Drug Interactions Using In Vitro Assays and Real-World Data. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 108-122	6.1	3
129	Drug Metabolites Potently Inhibit Renal Organic Anion Transporters, OAT1 and OAT3. <i>Journal of Pharmaceutical Sciences</i> , 2021 , 110, 347-353	3.9	4
128	Characterization of cytochrome P450 (CYP) 2D6 drugs as substrates of human organic cation transporters and multidrug and toxin extrusion proteins. <i>British Journal of Pharmacology</i> , 2021 , 178, 1459-1474	8.6	3
127	A New Era in Pharmacovigilance: Toward Real-World Data and Digital Monitoring. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 1197-1202	6.1	8
126	Advancing Precision Medicine Through the New Pharmacogenomics Global Research Network. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 559-562	6.1	4

125	Interaction of Commonly Used Oral Molecular Excipients with P-glycoprotein. <i>AAPS Journal</i> , 2021 , 23, 106	3.7	1
124	Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 16009-16018	11.5	15
123	GenEpi: gene-based epistasis discovery using machine learning. <i>BMC Bioinformatics</i> , 2020 , 21, 68	3.6	10
122	Interactions of Oral Molecular Excipients with Breast Cancer Resistance Protein, BCRP. <i>Molecular Pharmaceutics</i> , 2020 , 17, 748-756	5.6	12
121	Global Pharmacogenomics Within Precision Medicine: Challenges and Opportunities. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 57-61	6.1	17
120	Drug-nutrient interactions: discovering prescription drug inhibitors of the thiamine transporter ThTR-2 (SLC19A3). <i>American Journal of Clinical Nutrition</i> , 2020 , 111, 110-121	7	15
119	Expanding Precompetitive Multisector Collaborations to Advance Drug Development and Pharmacogenomics. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 96-101	6.1	3
118	The activities of drug inactive ingredients on biological targets. <i>Science</i> , 2020 , 369, 403-413	33.3	34
117	Scientific considerations for global drug development. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	6
116	Neural production of kynurenic acid in requires the AAT-1 transporter. <i>Genes and Development</i> , 2020 , 34, 1033-1038	12.6	1
115	Deorphaning a solute carrier 22 family member, SLC22A15, through functional genomic studies. <i>FASEB Journal</i> , 2020 , 34, 15734-15752	0.9	13
114	Unraveling the functional role of the orphan solute carrier, SLC22A24 in the transport of steroid conjugates through metabolomic and genome-wide association studies. <i>PLoS Genetics</i> , 2019 , 15, e1008208	6	14
113	Impact of Pharmaceutical Excipients on Oral Drug Absorption: A Focus on Intestinal Drug Transporters. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 323-325	6.1	7
112	l-Type amino acid transporter 1 activity of 1,2,3-triazolyl analogs of l-histidine and l-tryptophan. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019 , 29, 2254-2258	2.9	10
111	A Comprehensive Analysis of Ontogeny of Renal Drug Transporters: mRNA Analyses, Quantitative Proteomics, and Localization. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 1083-1092	6.1	45
110	Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug-Drug Interaction and Associated Biomarker Levels in Healthy Volunteers. <i>Clinical and Translational Science</i> , 2019 , 12, 388-399	4.9	26
109	Genome-Wide Association and Functional Studies Reveal Novel Pharmacological Mechanisms for Allopurinol. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 623-631	6.1	15
108	Functional and structural analysis of rare SLC2A2 variants associated with Fanconi-Bickel syndrome and metabolic traits. <i>Human Mutation</i> , 2019 , 40, 983-995	4.7	6

107	Research Projects Supported by the University of California, San Francisco-Stanford Center of Excellence in Regulatory Science and Innovation. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 815-818	6.1	3
106	A conserved role of the insulin-like signaling pathway in diet-dependent uric acid pathologies in <i>Drosophila melanogaster</i> . <i>PLoS Genetics</i> , 2019 , 15, e1008318	6	20
105	In Vitro Evaluation of Excipients as Inhibitors of Human Intestinal P-glycoprotein. <i>FASEB Journal</i> , 2019 , 33, 814.3	0.9	1
104	Organic cation transporter 3 (Oct3) is a distinct catecholamines clearance route in adipocytes mediating the beiging of white adipose tissue. <i>PLoS Biology</i> , 2019 , 17, e2006571	9.7	21
103	The Role of Transporters in Drug Accumulation and Mitochondrial Toxicity 2018 , 15-24		
102	Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 803-817	6.1	60
101	Genetic Variants in and Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes. <i>Diabetes</i> , 2018 , 67, 1428-1440	0.9	18
100	Molecular Mechanisms for Species Differences in Organic Anion Transporter 1, OAT1: Implications for Renal Drug Toxicity. <i>Molecular Pharmacology</i> , 2018 , 94, 689-699	4.3	29
99	Reverse Translational Research of ABCG2 (BCRP) in Human Disease and Drug Response. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 233-242	6.1	17
98	Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1). <i>Journal of Medicinal Chemistry</i> , 2018 , 61, 7358-7373	8.3	38
97	Organic cation transporter 1 (OCT1) modulates multiple cardiometabolic traits through effects on hepatic thiamine content. <i>PLoS Biology</i> , 2018 , 16, e2002907	9.7	29
96	Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 890-899	6.1	113
95	Emerging Clinical Importance of Hepatic Organic Cation Transporter 1 (OCT1) in Drug Pharmacokinetics, Dynamics, Pharmacogenetic Variability, and Drug Interactions. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 758-760	6.1	31
94	Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 836-864	6.1	77
93	Pharmacogenetics of Antidiabetic Drugs. <i>Advances in Pharmacology</i> , 2018 , 83, 361-389	5.7	9
92	ITC Commentary on Metformin Clinical Drug-Drug Interaction Study Design That Enables an Efficacy- and Safety-Based Dose Adjustment Decision. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 781-784	6.1	14
91	Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1). <i>Journal of Medicinal Chemistry</i> , 2017 , 60, 2685-2696	8.3	39
90	The Effect of Uremic Solutes on the Organic Cation Transporter 2. <i>Journal of Pharmaceutical Sciences</i> , 2017 , 106, 2551-2557	3.9	17

89	Transporters Involved in Metformin Pharmacokinetics and Treatment Response. <i>Journal of Pharmaceutical Sciences</i> , 2017 , 106, 2245-2250	3.9	72
88	Computational Discovery and Experimental Validation of Inhibitors of the Human Intestinal Transporter OATP2B1. <i>Journal of Chemical Information and Modeling</i> , 2017 , 57, 1402-1413	6.1	13
87	PharmGKB summary: very important pharmacogene information for ABCG2. <i>Pharmacogenetics and Genomics</i> , 2017 , 27, 420-427	1.9	14
86	Human Concentrative Nucleoside Transporter 3 (hCNT3, SLC28A3) Forms a Cyclic Homotrimer. <i>Biochemistry</i> , 2017 , 56, 3475-3483	3.2	9
85	Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine. <i>Nature Reviews Drug Discovery</i> , 2017 , 16, 1	64.1	59
84	LAT1 activity of carboxylic acid bioisosteres: Evaluation of hydroxamic acids as substrates. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016 , 26, 5000-5006	2.9	29
83	A research roadmap for next-generation sequencing informatics. <i>Science Translational Medicine</i> , 2016 , 8, 335ps10	17.5	29
82	The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 495-506	6.2	22
81	Rapid Method To Determine Intracellular Drug Concentrations in Cellular Uptake Assays: Application to Metformin in Organic Cation Transporter 1-Transfected Human Embryonic Kidney 293 Cells. <i>Drug Metabolism and Disposition</i> , 2016 , 44, 356-64	4	46
80	The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 711-21	6.2	37
79	Genomic Characterization of Metformin Hepatic Response. <i>PLoS Genetics</i> , 2016 , 12, e1006449	6	30
78	Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans. <i>Frontiers in Pharmacology</i> , 2016 , 7, 135	5.6	20
77	LAT-1 activity of meta-substituted phenylalanine and tyrosine analogs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016 , 26, 2616-2621	2.9	30
76	Identification and Quantitative Assessment of Uremic Solutes as Inhibitors of Renal Organic Anion Transporters, OAT1 and OAT3. <i>Molecular Pharmaceutics</i> , 2016 , 13, 3130-40	5.6	61
75	Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. <i>Nature Genetics</i> , 2016 , 48, 1055-1059	36.3	108
74	Targeted disruption of organic cation transporter 3 attenuates the pharmacologic response to metformin. <i>Molecular Pharmacology</i> , 2015 , 88, 75-83	4.3	62
73	SLC transporters as therapeutic targets: emerging opportunities. <i>Nature Reviews Drug Discovery</i> , 2015 , 14, 543-60	64.1	363
72	A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome. <i>Pharmacogenetics and Genomics</i> , 2015 , 25, 82-92	1.9	23

71	Prediction and validation of enzyme and transporter off-targets for metformin. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2015 , 42, 463-75	2.7	32
70	Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3). <i>Molecular Pharmaceutics</i> , 2015 , 12, 4301-10	5.6	61
69	Unmet needs: Research helps regulators do their jobs. <i>Science Translational Medicine</i> , 2015 , 7, 315ps22	17.5	11
68	Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations. <i>Clinical Pharmacokinetics</i> , 2014 , 53, 283-293	6.2	67
67	OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 9983-8	11.5	155
66	Metformin pharmacogenomics: current status and future directions. <i>Diabetes</i> , 2014 , 63, 2590-9	0.9	90
65	Genome-wide discovery of drug-dependent human liver regulatory elements. <i>PLoS Genetics</i> , 2014 , 10, e1004648	6	30
64	A genome-wide association study of bronchodilator response in Latinos implicates rare variants. <i>Journal of Allergy and Clinical Immunology</i> , 2014 , 133, 370-8	11.5	84
63	Gene expression profiling of transporters in the solute carrier and ATP-binding cassette superfamilies in human eye substructures. <i>Molecular Pharmaceutics</i> , 2013 , 10, 650-63	5.6	41
62	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. <i>Journal of Medicinal Chemistry</i> , 2013 , 56, 781-795	8.3	100
61	Renal transporters in drug development. <i>Annual Review of Pharmacology and Toxicology</i> , 2013 , 53, 503-297.9	226	
60	The Pharmacogenomics of Membrane Transporters Project 2013 , 73-108		
59	OCT (SLC22A) and OCTN Family 2013 , 171-208		5
58	Reduced renal clearance of cefotaxime in asians with a low-frequency polymorphism of OAT3 (SLC22A8). <i>Journal of Pharmaceutical Sciences</i> , 2013 , 102, 3451-7	3.9	41
57	Structure-based ligand discovery for the Large-neutral Amino Acid Transporter 1, LAT-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 5480-5	11.5	129
56	Molecular modeling and ligand docking for solute carrier (SLC) transporters. <i>Current Topics in Medicinal Chemistry</i> , 2013 , 13, 843-56	3	65
55	High selectivity of the β -aminobutyric acid transporter 2 (GAT-2, SLC6A13) revealed by structure-based approach. <i>Journal of Biological Chemistry</i> , 2012 , 287, 37745-56	5.4	41
54	Pharmacogenomics and patient care: one size does not fit all. <i>Science Translational Medicine</i> , 2012 , 4, 153ps18	17.5	39

53	The role of ATM in response to metformin treatment and activation of AMPK. <i>Nature Genetics</i> , 2012 , 44, 359-60	36.3	44
52	Metformin pathways: pharmacokinetics and pharmacodynamics. <i>Pharmacogenetics and Genomics</i> , 2012 , 22, 820-7	1.9	256
51	Germline Genetic Polymorphisms Are Associated with Disease-Free Survival in Adults with Acute Myeloid Leukemia (AML): A Genomewide Association Study From the Pgrn-Riken Global Alliance.. <i>Blood</i> , 2012 , 120, 2548-2548	2.2	
50	Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. <i>Journal of Medicinal Chemistry</i> , 2011 , 54, 4548-58	8.3	117
49	Role of organic cation transporter 1, OCT1 in the pharmacokinetics and toxicity of cis-diammine(pyridine)chloroplatinum(II) and oxaliplatin in mice. <i>Pharmaceutical Research</i> , 2011 , 28, 610-23	4.5	36
48	Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 15810-5	11.5	101
47	Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 531-9	6.1	145
46	SLCO1B1 Variation and Methotrexate Disposition in Children with Acute Lymphoblastic Leukemia: The Importance of Rare Variants in Pharmacogenetics. <i>Blood</i> , 2011 , 118, 571-571	2.2	
45	Membrane transporters in drug development. <i>Nature Reviews Drug Discovery</i> , 2010 , 9, 215-36	64.1	2464
44	Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue. <i>Molecular Cancer Therapeutics</i> , 2010 , 9, 1058-69	6.1	66
43	Genetic variants of human organic anion transporter 4 demonstrate altered transport of endogenous substrates. <i>American Journal of Physiology - Renal Physiology</i> , 2010 , 299, F767-75	4.3	18
42	Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. <i>Pharmacogenetics and Genomics</i> , 2010 , 20, 687-99	1.9	145
41	Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. <i>Pharmacogenetics and Genomics</i> , 2009 , 19, 497-504	1.9	184
40	Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. <i>Pharmacogenomics Journal</i> , 2009 , 9, 127-36	3.5	87
39	Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1. <i>Pharmacogenetics and Genomics</i> , 2009 , 19, 770-80	1.9	52
38	Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variation. <i>PLoS ONE</i> , 2009 , 4, e6942	3.7	33
37	cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 8902-7	11.5	198
36	Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. <i>Molecular Pharmacology</i> , 2008 , 73, 1151-8	4.3	91

35	Genetic variation in human aquaporins and effects on phenotypes of water homeostasis. <i>Human Mutation</i> , 2008 , 29, 1108-17	4.7	18
34	Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion family. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007 , 322, 695-700	4.7	88
33	Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4). <i>Pharmacogenetics and Genomics</i> , 2007 , 17, 773-82	1.9	39
32	Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. <i>Journal of Clinical Investigation</i> , 2007 , 117, 1422-31	15.9	673
31	The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics. <i>American Journal of Physiology - Renal Physiology</i> , 2006 , 290, F905-12	4.3	78
30	Organic cation transporters are determinants of oxaliplatin cytotoxicity. <i>Cancer Research</i> , 2006 , 66, 8847-51	4.5	339
29	Functional genetic diversity in the high-affinity carnitine transporter OCTN2 (SLC22A5). <i>Molecular Pharmacology</i> , 2006 , 70, 1602-11	4.3	46
28	Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1). <i>Pharmacogenetics and Genomics</i> , 2005 , 15, 201-9	1.9	81
27	The concentrative nucleoside transporter family, SLC28. <i>Pflugers Archiv European Journal of Physiology</i> , 2004 , 447, 728-34	4.6	304
26	Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 5896-901	11.5	208
25	Sorting of rat SPNT in renal epithelium is independent of N-glycosylation. <i>Pharmaceutical Research</i> , 2003 , 20, 319-23	4.5	14
24	Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 5902-7	11.5	241
23	Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. <i>Pharmacogenetics and Genomics</i> , 2002 , 12, 395-405		169
22	Arginine 454 and lysine 370 are essential for the anion specificity of the organic anion transporter, rOAT3. <i>Biochemistry</i> , 2001 , 40, 5511-20	3.2	67
21	Molecular determinants of substrate selectivity in Na ⁺ -dependent nucleoside transporters. <i>Journal of Biological Chemistry</i> , 1997 , 272, 28845-8	5.4	46
20	Cloning and functional expression of a human liver organic cation transporter. <i>Molecular Pharmacology</i> , 1997 , 51, 913-21	4.3	343
19	Taurine transport in cultured choroid plexus. <i>Pharmaceutical Research</i> , 1997 , 14, 406-9	4.5	8
18	Mechanisms of 5-fluorouracil (5-FU) transport in isolated rabbit choroid plexus tissue slices. <i>Pharmaceutical Research</i> , 1996 , 13, 1276-8	4.5	5

17	Expression of a renal Na(+)-nucleoside cotransport system (N2) in <i>Xenopus laevis</i> oocytes. <i>Pflugers Archiv European Journal of Physiology</i> , 1994 , 427, 381-3	4.6	12
16	Interaction of nucleoside analogues with the sodium-nucleoside transport system in brush border membrane vesicles from human kidney. <i>Pharmaceutical Research</i> , 1993 , 10, 423-6	4.5	55
15	Stereoselective interactions of organic cations with the organic cation transporter in OK cells. <i>Pharmaceutical Research</i> , 1993 , 10, 1169-73	4.5	16
14	Formycin B elimination from the cerebrospinal fluid of the rat. <i>Pharmaceutical Research</i> , 1993 , 10, 611-5	4.5	10
13	Effect of probenecid on the pharmacokinetics and pharmacodynamics of procainamide. <i>Journal of Clinical Pharmacology</i> , 1991 , 31, 429-32	2.9	4
12	The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose. <i>Clinical Pharmacology and Therapeutics</i> , 1989 , 46, 408-19	6.1	41
11	The pharmacokinetics of the enantiomers of atenolol. <i>Clinical Pharmacology and Therapeutics</i> , 1989 , 45, 403-10	6.1	38
10	The effect of probenecid on the renal elimination of cimetidine. <i>Clinical Pharmacology and Therapeutics</i> , 1989 , 45, 444-52	6.1	44
9	Renal transport of drugs: an overview of methodology with application to cimetidine. <i>Pharmaceutical Research</i> , 1988 , 5, 465-71	4.5	7
8	Cimetidine elimination from the cerebrospinal fluid of the rat. <i>Pharmaceutical Research</i> , 1988 , 5, 628-33	4.5	3
7	Stereoselective binding of disopyramide to plasma proteins. <i>Pharmaceutical Research</i> , 1988 , 5, 316-8	4.5	7
6	Verapamil interacts stereoselectively with the muscarinic receptor. <i>Pharmaceutical Research</i> , 1985 , 2, 94-5	4.5	
5	Correction for Volume Shift during Equilibrium Dialysis by Measurement of Protein Concentration. <i>Pharmaceutical Research</i> , 1984 , 1, 179-81	4.5	14
4	Effect of concentration-dependent binding to plasma proteins on the pharmacokinetics and pharmacodynamics of disopyramide. <i>Clinical Pharmacokinetics</i> , 1984 , 9 Suppl 1, 42-8	6.2	14
3	Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt. <i>Clinical Pharmacology and Therapeutics</i> , 1980 , 28, 417-24	6.1	24
2	Effect of hemodialysis on propoxyphene and norpropoxyphene concentrations in blood of anephric patients. <i>Clinical Pharmacology and Therapeutics</i> , 1980 , 27, 508-14	6.1	27
1	Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient. <i>Clinical Pharmacology and Therapeutics</i> , 1980 , 27, 665-70	6.1	54